GENPF (Genix Pharmaceuticals) Total Liabilities: $1.09 Mil (As of Jan. 2026)


What is Genix Pharmaceuticals Total Liabilities?

Genix Pharmaceuticals GENPF Total Liabilities is $1.09 Mil as of Jan. 2026. The stock has 3 warning signs investors should review.

Genix Pharmaceuticals's Total Liabilities for the quarter that ended in Jan. 2026 was $1.09 Mil.

Genix Pharmaceuticals's quarterly Total Liabilities declined from Jul. 2025 ($1.06 Mil) to Oct. 2025 ($1.05 Mil) but then increased from Oct. 2025 ($1.05 Mil) to Jan. 2026 ($1.09 Mil).

Genix Pharmaceuticals's annual Total Liabilities declined from Oct. 2023 ($0.99 Mil) to Oct. 2024 ($0.89 Mil) but then increased from Oct. 2024 ($0.89 Mil) to Oct. 2025 ($1.05 Mil).

Genix Pharmaceuticals Total Liabilities Historical Data

* Premium members only.

The historical data trend for Genix Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genix Pharmaceuticals Total Liabilities Chart

Genix Pharmaceuticals Annual Data
Trend Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.61 0.77 0.99 0.89 1.05

Genix Pharmaceuticals Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.94 0.99 1.06 1.05 1.09

Genix Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Genix Pharmaceuticals's Total Liabilities for the fiscal year that ended in Oct. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.051+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=1.05

Total Liabilities=Total Assets (A: Oct. 2025 )-Total Equity (A: Oct. 2025 )
=0.036--1.014
=1.05

Genix Pharmaceuticals's Total Liabilities for the quarter that ended in Jan. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.094+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=1.09

Total Liabilities=Total Assets (Q: Jan. 2026 )-Total Equity (Q: Jan. 2026 )
=0.025--1.068
=1.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $1.09 Mil mean?
Genix Pharmaceuticals (GENPF) has a Total Liabilities of $1.09 Mil as of Jan. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Genix Pharmaceuticals and its competitors.
Is Genix Pharmaceuticals' Total Liabilities too high?
Genix Pharmaceuticals' current Total Liabilities is $1.09 Mil.
How does Genix Pharmaceuticals' Total Liabilities compare to ZTS and UTHR?
Genix Pharmaceuticals' Total Liabilities of $1.09 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Genix Pharmaceuticals and its competitors. Genix Pharmaceuticals's current Total Liabilities is $1.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genix Pharmaceuticals stock overvalued right now?
Genix Pharmaceuticals (GENPF) has a current Total Liabilities of $1.09 Mil. The current Total Liabilities is $1.09 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Genix Pharmaceuticals (GENPF), the current Total Liabilities is $1.09 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genix Pharmaceuticals Business Description

Other Exchanges GENX:Canada
Address 1055 West Hastings Street, Suite 300, Vancouver, BC, CAN, V6E 1J8
Genix Pharmaceuticals Corp is a Canadian life sciences company focused on the research, development, manufacturing, sales, and distribution of novel, branded generic ophthalmic drugs, and ophthalmic OTC products. It operates as a formulator, manufacturer, licensor, and marketer of life sciences-related products with a focus on nutraceuticals and pharmaceuticals. Its ophthalmic products portfolio comprises different kinds of eye ointments (pending approval), and eye drops. Geographically the company operates only in Canada.